IN THE CLAIMS

Please amend the claims as follows:

Claims 1-20 (Cancelled).

Claim 21 (Currently Amended): A composition, comprising:

an extremely poorly water-soluble drug; and

a porous silica material;

wherein:

the composition is obtained by treating a mixture comprising the porous silica material and the extremely poorly water-soluble drug with a supercritical fluid or subcritical fluid of carbon dioxide;

the extremely poorly water-soluble drug has a solubility in water at 25 °C of less than 10 μg/mL prior to treatment; and

the porous silica material has an average pore diameter ~~in a range~~ of from 1 to 20 nm, a total pore volume of ~~where~~ pores having diameters within ±40% of the average pore ~~size account~~ diameter accounts for at least 60% of a ~~total pore~~ volume of all pores of the porous silica material, and the porous silica material has an X-ray diffraction ~~spectrum~~ pattern including at least one peak at a position of a diffraction angle (2θ) corresponding to a *d* value of at least 1 nm.

Claim 22 (Previously Presented): The composition according to claim 21, wherein the porous silica material has a specific surface area of from 100 to 2,000 m^2/g.

Claim 23 (Previously Presented): The composition according to claim 21, wherein a mixing ratio the porous silica material to the extremely poorly water-soluble drug is from 0.1:1 to 1,000:1.

Claim 24 (Previously Presented): The composition according to claim 21, wherein the extremely poorly water-soluble drug comprises 2-benzyl-5-(4-chlorophenyl)-6-[4-(methylthio)phenyl]-2H-pyridazin-3-one.

Claim 25 (Withdrawn – Currently Amended): A medicinal preparation comprising ~~a~~ the composition ~~with an extremely poorly water-soluble drug contained therein as defined in~~ according to claim 21.

Claim 26 (Withdrawn – Currently Amended): A process for producing ~~a~~ the composition ~~with an extremely poorly water-soluble drug contained therein as defined in~~ according to claim 21, ~~the process~~ comprising:

placing a porous silica material and ~~said~~ an extremely poorly water-soluble drug in a pressure-resistant vessel;

filling ~~said~~ the pressure-resistant vessel with carbon dioxide;

~~treating said porous silica material and said extremely poorly water-soluble drug while controlling~~ maintaining the vessel at a temperature and pressure ~~within said vessel~~ such that the carbon dioxide is maintained ~~in~~ as a supercritical ~~state~~ fluid or a subcritical ~~state~~fluid; and

discharging the carbon dioxide to recover the resulting composition~~,~~;

wherein ~~said~~ the porous silica material has an average pore diameter ~~in a range~~ of from 1 to 20 nm, a total pore volume of pores having diameters within ±40% of ~~said~~ the

average pore ~~size account~~ diameter accounts for at least 60% of a ~~total pore~~ volume of all pores of ~~said~~ the porous silica material, and ~~in~~ the porous silica material has an X-ray ~~diffractometry, said porous silica material has~~ diffraction pattern including at least one peak at a position of a diffraction angle (2θ) corresponding to a *d* value of at least 1 nm.

Claim 27 (Withdrawn – Currently Amended): The process of claim 26, wherein a weight ratio of ~~said~~ the extremely poorly water-soluble drug to ~~a~~ the supercritical fluid or subcritical fluid of carbon dioxide is from 1:1 to 1:1,000,000.

Claim 28 (Withdrawn – Currently Amended): The process of claim 26, wherein maintaining the vessel comprises maintaining the vessel at a temperature of ~~treatment with a supercritical fluid or subcritical fluid is~~ from – 40 to 100°C.

Claim 29 (Withdrawn – Currently Amended): The process of claim 26, wherein maintaining the vessel comprises maintaining the vessel at a pressure of ~~treatment with a supercritical fluid or subcritical fluid is~~ from 1 to 50 MPa.

Claim 30 (Withdrawn – Currently Amended): The process of claim 26, wherein the porous silica material and the extremely poorly water-soluble drug are maintained in contact with the ~~a time of treatment with a~~ supercritical fluid or subcritical fluid of carbon dioxide ~~is~~ for a period of from 1 minute to 24 hours.

Claim 31 (Withdrawn – Currently Amended): A process for producing a composition ~~with an extremely poorly water-soluble drug contained therein as defined in~~ according to claim 21, ~~the process~~ comprising:

placing a porous silica material and ~~said~~ an extremely poorly water-soluble drug in a pressure-resistant vessel;

maintaining ~~controlling~~ the vessel at a temperature ~~within said vessel such that~~ at which carbon dioxide ~~will be maintained~~ is in ~~a~~ the form of a supercritical ~~state~~ fluid or a subcritical ~~state~~fluid;

-filling ~~said pressure~~ the vessel with carbon dioxide at ~~such~~ a pressure such that carbon dioxide is ~~maintained~~ in ~~said~~ the form of a supercritical ~~state~~ fluid or a subcritical ~~state~~fluid;

~~maintaining said supercritical state or subcritical state to treat said~~ treating the ~~poruous~~ porous silica material and ~~said~~ the extremely poorly water-soluble drug with the supercritical fluid or subcritical fluid of carbon dioxide; and

discharging carbon dioxide to recover the resulting composition~~,~~;

wherein ~~said~~ the porous silica material has an average pore diameter ~~in a range~~ of from 1 to 20 nm, a total pore volume of pores having diameters within ±40% of ~~said~~ the average pore ~~size account~~ diameter accounts for at least 60% of a ~~total pore~~ volume of ~~said~~ all pores of the porous silica material, and the porous silica material has an ~~in~~ X-ray ~~diffractometry, said porous silica material has~~ diffraction pattern including at least one peak at a position of a diffraction angle (2θ) corresponding to a *d* value of at least 1 nm.

Claim 32 (Withdrawn – Currently Amended): The process according to claim 31, wherein a weight ratio of ~~said~~ the extremely poorly water-soluble drug to ~~a~~ the supercritical fluid or subcritical fluid of carbon dioxide is from 1:1 to 1:1,000,000.

Claim 33 (Withdrawn – Currently Amended): The process according to claim 31, wherein treating the porous silica material and the extremely poorly water-soluble drug

comprises treating at a temperature of ~~treatment with a supercritical fluid or subcritical fluid is~~ from – 40 to 100°C.

Claim 34 (Withdrawn – Currently Amended): The process according to claim 31, wherein treating the porous silica material and the extremely poorly water-soluble drug comprises treating at a pressure of ~~treatment with a supercritical fluid or subcritical fluid is~~ from 1 to 50 MPa.

Claim 35 (Withdrawn – Currently Amended): The process according to claim 31, wherein treating the porous silica material and the extremely poorly water-soluble drug comprises treating for a period of ~~a time of treatment with a supercritical fluid or subcritical fluid is~~ from 1 minute to 24 hours.